Author

admin

Browsing

The copper price climbed to a fresh record on Tuesday (January 6), with persistent supply disruptions and trade uncertainty pushing the metal to a nearly 30 percent rally since October.

Benchmark three month copper on the London Metal Exchange (LME) rose as much as 3.1 percent in early trading to an all‑time high of US$13,387.50 per metric ton before settling slightly lower, but still above US$13,200.

The jump marks another milestone in a rally that first saw copper breach US$12,000 late in December last year.

Copper is widely used across the industrial economy, from construction and power infrastructure to electric vehicles and data centers that support artificial intelligence growth. Analysts attribute the gains to a combination of production setbacks at major mines and heightened concerns that prospective US trade tariffs could further disrupt flows.

Large copper-mining operations such as Freeport-McMoRan’s (NYSE:FCX) Grasberg complex in Indonesia have faced challenges since last year, while a strike at Capstone Copper’s (TSX:CS,ASX:CSC,OTC Pink:CSCCF) Mantoverde mine in Chile has reduced output prospects in one of the world’s top copper‑producing nations.

The threat of new tariffs under the Trump administration has also shaped expectations. Traders have moved to ship refined copper into the US ahead of any potential levies, tightening supply elsewhere. Furthermore, data show copper stocks in Comex warehouses have jumped to more than 450,000 metric tons, well above last year’s levels.

Copper outlook for 2026

Market watchers expect many of the forces that drove copper through 2025 to persist.

Supply constraints are expected to remain acute this year as aging mines and capacity shortfalls weigh on availability. New projects such as Arizona Sonoran Copper Company’s (TSX:ASCU,OTCQX:ASCUF) Cactus project and the long‑anticipated Resolution mine in the US are still years from significant output.

Copper demand is projected to grow as the global energy transition accelerates.

“A huge amount of this tightness has to do with US tariff concerns,” she said.

China, the world’s largest copper consumer, is also shaping the outlook. Despite weakness in its property sector, the country posted economic growth and is expected to prioritize copper‑intensive sectors under its new five year plan.

Longer‑term projections from industry groups suggest structural demand growth will outpace supply additions.

A UN report estimates that copper demand could rise 40 percent by 2040, requiring substantial investment and new mines just to keep pace. Likewise, Wood Mackenzie forecasts that copper demand will increase 24 percent by 2035, while the International Copper Study Group predicts a refined copper deficit of 150,000 metric tons in 2026 alone.

Securities Disclosure: I, Giann Liguid, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Discoveries made by companies in the genetics sector help support every other life science industry in a variety of ways.

One of the genetic sector’s major contributions is the discovery of new genetic drivers of diseases. Genetic testing has grown substantially over the last few years, thanks to advances in technology; growth has also been spurred by an increase in chronic diseases and the continuing development of test kits for therapeutic areas with unmet medical needs.

Gene therapy is also a huge driver of growth in the overarching genetics market. This important segment of the life science market is focused on how genes can help treat or prevent serious conditions in patients. This includes the potential for healthcare professionals to implement gene therapy at the cellular level instead of using medication or surgery, replacing ‘faulty’ genes with new ones to potentially cure diseases.

Pharma and biotech companies often dabble in genetics along with their core disciplines, meaning that some firms may also have operations in other areas.

The top NASDAQ genetics stocks listed below have products related to gene therapy, genetic testing, genetically defined cancers and rare genetic diseases.

Data for this list of genetics stocks on the NASDAQ was collected on December 31, 2025, using TradingView’s stock screener, and stocks with market caps above US$50 million were considered.

1. Avidity Biosciences (NASDAQ:RNA)

Year-over-year gain: 143.8 percent
Market cap: US$10.87 billion
Share price: US$72.14

Avidity Bioscience is a biopharma firm developing a new form of RNA therapy called antibody oligonucleotide conjugates (AOC) that target the genes causing rare muscle diseases.

Through its proprietary AOC platform, Avidity developed programs for three rare muscle diseases: AOC 1001 for myotonic dystrophy type 1, AOC 1044 for Duchenne muscular dystrophy and AOC 1020 for facioscapulohumeral muscular dystrophy. The company is also working to expand its pipeline into cardiology and immunology.

In October 2025, Avidity entered into a definitive agreement to be acquired by Novartis (NYSE:NVS), which will include the company’s late-stage neuromuscular programs (AOC 1001, 1020, 1044) and the AOC platform, for US$12 billion.

Avidity’s early-stage precision cardiology programs will spin off into a new public company prior to closing in H1 2026. The spin-off will also have rights to use and develop the AOC platform for cardiology applications.

2. Wave Life Sciences (NASDAQ:WVE)

Year-over-year gain: 36.52 percent
Market cap: US$3.13 billion
Share price: US$17.12

Wave Life Sciences is another clinical-stage firm focused on unlocking insights from human genetics to deliver RNA-based medicines. The company’s PRISM platform is targeting both rare and prevalent disorders. Its pipeline includes clinical programs for Duchenne muscular dystrophy, alpha-1 antitrypsin deficiency and Huntington’s disease, as well as a preclinical program for WVE-007 in obesity.

Wave Life Sciences advanced its PRISM RNA platform across multiple programs in 2025. It is also performing a Phase 1 trial testing its WVE-007 obesity candidate, which is an investigational INHBE GalNAc-siRNA using Wave’s proprietary SpiNA design.

In December, the company reported positive interim data from the WVE-007 trial, which showed that a single dose resulted in sustained Activin E reduction, supporting infrequent dosing. Target engagement updates and body composition readouts are planned for Q1 2026.

3. UniQure (NASDAQ:QURE)

Year-over-year gain: 33.15 percent
Market cap: US$1.47 billion
Share price: US$23.86

UniQure is a gene therapy company focused on patients with severe medical needs. In November 2022, the US Food and Drug Administration (FDA) approved the company’s gene therapy Hemgenix (etranacogene dezaparvovec), which is the world’s first gene therapy for hemophilia B.

Today, uniQure’s proprietary gene therapy pipeline includes treatments for patients with Huntington’s disease, refractory temporal lobe epilepsy, ALS and Fabry disease.

Its gene therapy pipeline advanced in 2025, with positive Phase I/II topline data for Huntington’s disease candidate AMT-130 showing 75 percent slowing of disease progression at three years via cUHDRS, alongside 60 percent functional capacity preservation.

While data from the Phase I/II study led the FDA to grant AMT-130 breakthrough therapy designation in April, in December the agency told UniQure it believes the data may not be adequate to support a pre-biologics license application under the accelerated approval pathway. The company is pursuing a follow-up meeting.

4. Stoke Therapeutics (NASDAQ:STOK)

Year-over-year gain: 186.96 percent
Market cap: US$1.81 billion
Share price: US$31.74

Stoke Therapeutics is another biotech company with a focus on developing RNA medicine. With its proprietary research platform TANGO, which stands for targeted augmentation of nuclear gene output, the company is developing antisense oligonucleotides to selectively restore protein levels.

Stoke’s first product candidate, zorevunersen (STK-001), is in clinical testing for the treatment of Dravet syndrome, a severe form of genetic epilepsy. The company is also developing STK-002 for the treatment of autosomal dominant optic atrophy, an inherited optic nerve disorder.

Both candidates advanced in 2025, with STK-001 enrolling patients in Phase 3 after positive long-term data showed seizure reductions and cognitive gains. Likewise, STK-002’s clinical development program is being informed by results, presented in October, of a Phase 1 two year natural history study on the disease progression of autosomal dominant optic atrophy.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

Sen. Ted Cruz, R-Texas, on Wednesday called on Congress during a Senate hearing to impeach two federal judges, making his most elaborate case yet for imposing the extraordinary sanction on a pair of closely scrutinized jurists.

Cruz acknowledged that impeaching federal judges is exceedingly rare — 15 have been impeached in history, typically for straightforward crimes like bribery — but the Texas Republican argued it was warranted for judges James Boasberg and Deborah Boardman.

‘Rarer still, until now, were the deeper offenses the framers feared most — judges who, without necessarily breaking a criminal statute, violate the public trust, subvert the constitutional order or wield their office in ways that injure society itself,’ Cruz said. ‘That is why, throughout history, Congress recognized that impeachable misconduct need not be criminal.’

Cruz, a Senate Judiciary Committee member with an extensive legal background, said the House needed to initiate impeachment proceedings over controversial gag orders Boasberg signed in 2023 and a sentence Boardman handed down last year in the case of Justice Brett Kavanaugh’s attempted assassin.

Impeachment proceedings must be initiated in the House and typically run through the House Judiciary Committee.

Russell Dye, a spokesman for the GOP-led committee, said ‘everything is on the table’ when asked if Chairman Jim Jordan, R-Ohio, was open to the idea. If the House were to vote in favor of impeachment, it would then advance to the Senate. Two-thirds of senators would need to vote to convict the judges and remove them, a highly improbable scenario because the vote would require some support from Democrats.

Cruz’s counterpart at the hearing, Sen. Sheldon Whitehouse, D-R.I., defended the judges and accused Republicans of threatening impeachment as an effort to intimidate the judiciary because it routinely issues adverse rulings against the Trump administration.

‘There was a time when I’d have hoped a Senate Judiciary subcommittee would not be roped into a scheme to amplify pressure and threats against a sitting federal judge,’ Whitehouse said. ‘But here we are.’

In the case of Boardman, a Biden appointee, the judge sentenced Sophie Roske, who previously went by Nicholas Roske, to eight years in prison after the Department of Justice sought a 30-year sentence. Roske pleaded guilty to attempting to murder Kavanaugh. Boardman said she factored into her sentence that Roske identified as transgender and therefore faced unique adversity.

Cruz argued Democrats’ concerns about threats that judges have faced for ruling against President Donald Trump fell on deaf ears, in his view, because they did not speak out about Boardman’s leniency toward Roske.

‘My Democrat colleagues on this committee do not get to give great speeches about how opposed they are to violence against the judiciary, and, at the same time, cheer on a judge saying, ‘Well, if you attempt to murder a Supreme Court justice, and you happen to be transgender, not a problem. We’re going to deviate downward by more than two decades,” Cruz said.

In the case of Boasberg, former special counsel Jack Smith subpoenaed several Republican Congress members’ phone records while conducting an investigation into the 2020 election and Trump’s role in the Jan. 6 Capitol riot. Smith sought gag orders so that the senators would not immediately be notified about the subpoenas, and Boasberg authorized those orders.

Prosecutors seeking gag orders is not unusual, but senators have layers of protection from prosecution under the Constitution. The targeted Republicans have decried the subpoenas, saying their rights were violated.

Smith and an official representing the federal courts have both said that Boasberg was not notified that the subpoenas and gag orders were related to members of Congress.

Rob Luther, a law professor at George Mason University, was a witness for Republicans at the hearing and said Boasberg still should not have signed the gag orders without knowing who they applied to. Luther cited stipulations included in the orders.

‘One must ask on what basis Judge Boasberg found that the disclosure of subpoenas would result in destruction of or tampering with evidence, intimidation of potential witnesses, and cause serious jeopardy to the investigation, end quote,’ Luther said. ‘Did Judge Boasberg merely rubber stamp the requested gag order, or was he willfully blind?’

Smith’s actions also aligned with a DOJ policy at the time that did not require the special counsel to alert the court that the subpoenas targeted senators, a point raised by Sen. John Kennedy, R-La., during the hearing. Luther said the policy did not matter.

‘DOJ policy does not supplant federal law,’ he said.

This post appeared first on FOX NEWS

Sen. Lindsey Graham announced Wednesday that President Donald Trump has approved a Russian sanctions bill designed to pressure Moscow to end its war with Ukraine.

Graham revealed the development in a post on X, describing it as a pivotal shift in the U.S. approach to the Russia-Ukraine conflict. 

‘After a very productive meeting today with President Trump on a variety of issues, he greenlit the bipartisan Russia sanctions bill that I have been working on for months with Senator Blumenthal and many others,’ Graham said. 

‘This will be well-timed, as Ukraine is making concessions for peace and Putin is all talk, continuing to kill the innocent.’

According to the Sanctioning Russia Act of 2025, the bipartisan legislation is designed to grant Trump sweeping, almost unprecedented, authority to economically isolate Russia and penalize major global economies that continue to trade with Moscow and finance its war against Ukraine.

Most notably, the bill would require the United States to impose a 500% tariff on all goods imported from any country that continues to purchase Russian oil, petroleum products or uranium. The measure would effectively squeeze Russia financially while deterring foreign governments from undermining U.S. sanctions.

‘This bill will allow President Trump to punish those countries who buy cheap Russian oil fueling Putin’s war machine,’ Graham said.

‘This bill would give President Trump tremendous leverage against countries like China, India and Brazil to incentivize them to stop buying the cheap Russian oil that provides the financing for Putin’s bloodbath against Ukraine.’

Graham said voting could take place as early as next week and that he is looking forward to a strong bipartisan vote.

The move on the Russian sanctions bill follows another sharp escalation in America’s clampdown on Moscow. Earlier Wednesday, U.S. forces reportedly seized an oil tanker attempting to transport sanctioned Venezuelan oil to Russia.

Graham publicly celebrated the seizure in another post on X, describing it as part of a broader winning streak of U.S. intervention aimed at Venezuela and Cuba. 

In the post, he also took aim at critics such as Sen. Rand Paul, who has opposed the bill, arguing that it would damage America’s trade relations with much of the world.

Fox News Digital reached out to the White House for comment.

This post appeared first on FOX NEWS

The seizure of a Russian-linked oil tanker in the North Atlantic has highlighted ‘worry’ among NATO and Nordic-Baltic governments over dark fleet vessels and the type of crews onboard, according to a maritime intelligence analyst.

U.S. military and Coast Guard personnel boarded the Marinera between Iceland and the U.K. Wednesday as it operated under deceptive shipping practices, including flying a false flag and violating sanctions.

According to Reuters, Russian authorities demanded the humane treatment and repatriation of the crew members.

Windward maritime intelligence analyst Michelle Wiese Bockmann claimed the Marinera’s ownership had just been transferred to Burevestmarin LLC, a Russian company.

‘We do not know the status of these sailors and seafarers, who are Russian nationals,’ Wiese Bockmann told Fox News Digital. ‘That lack of clarity is common with dark fleet tankers.

‘The Marinera did have its ownership transferred to a newly formed Russian company, with the registered owner, ship manager and commercial manager being Burevestmarin LLC.’

She also suggested NATO and the Nordic-Baltic 8+ group of governments have been ‘worried’ about sanctioned oil tankers with unauthorized personnel onboard, including ‘armed guards.’

‘Increasingly, and I know the Nordic Baltic 8+ governments are worried about the fact that you are having unauthorized people also on board, also known as armed guards,’ Wiese Bockmann said. ‘But it is highly irregular.

‘Armed guards are rarely seen and typically used on ships that are transiting the Gulf of Aden or the Red Sea and are therefore assessed as at risk from attack by Houthis or pirates,’ she added.

After the seizure, White House press secretary Karoline Leavitt rejected Russian demands for special treatment of the Marinera’s crew during her regular briefing Wednesday.

‘This was a Venezuelan shadow fleet vessel that had transported sanctioned oil,’ Leavitt said.

‘The vessel was deemed stateless after flying a false flag, and it had a judicial seizure order. And that’s why the crew will be subject to prosecution.’

Russia’s Foreign Ministry said it was ‘closely following’ the situation, according to the state-run TASS news agency.

Wiese Bockmann noted that dark fleet crews are often multinational, typically involving a Russian master with Chinese, Indian or Filipino crew members.

‘There is a blurring of commercial and military shipping around the dark fleet,’ she said. ‘What we’re seeing now is something that has really only emerged in the last six or seven months.’

European authorities have also begun holding crews accountable, particularly when captains are ‘facilitating dangerous deceptive shipping practices, such as spoofing and going dark,’ she explained.

‘The EU recently sanctioned the captain of a tanker who refused orders from the Estonian navy (Jaguar) to be stopped for inspection last May. And the French charged a captain over his refusal to comply with orders and failure to justify a flag’s nationality after authorities intercepted a dark fleet tanker in the Atlantic last October,’ Wiese Bockmann added.

As previously reported by Fox News Digital, a second vessel, the M. Sophia, was also boarded in international waters near the Caribbean while en route to Venezuela.

Fox News Digital has reached out to the White House for comment.

This post appeared first on FOX NEWS

President Donald Trump on Wednesday signed a presidential memorandum directing the U.S. to withdraw from 66 international organizations, ordering executive departments and agencies to cease participation in and funding of entities the administration says no longer serve U.S. interests.

The memorandum follows a State Department review ordered earlier this year under Executive Order 14199 and applies to 35 non-United Nations organizations and 31 United Nations entities, according to the White House.

In the memorandum, Trump said he reviewed Secretary Rubio’s findings and determined it is ‘contrary to the interests of the U.S. to remain a member of, participate in, or otherwise provide support’ to the listed organizations.

The order directs all executive departments and agencies to take immediate steps to effectuate the withdrawals as soon as possible. For United Nations entities, withdrawal means ceasing participation in or funding to the extent permitted by law.

The administration framed the move as part of Trump’s broader ‘America First’ agenda aimed at restoring American sovereignty and ending taxpayer support for organizations it views as wasteful, ineffective or contrary to U.S. interests. 

Review of additional international organizations remains ongoing, according to the White House.

Secretary of State Marco Rubio said the withdrawals fulfill a key commitment of Trump’s presidency.

‘Today, President Trump announced the U.S. is leaving 66 anti-American, useless, or wasteful international organizations,’ Rubio said in a post on X. ‘Review of additional international organizations remains ongoing.’

Rubio said the administration concluded the institutions were ‘redundant in their scope, mismanaged, unnecessary, wasteful, poorly run, captured by the interests of actors advancing their own agendas contrary to our own, or a threat to our nation’s sovereignty, freedoms, and general prosperity.’

‘It is no longer acceptable to be sending these institutions the blood, sweat, and treasure of the American people, with little to nothing to show for it,’ Rubio said. ‘The days of billions of dollars in taxpayer money flowing to foreign interests at the expense of our people are over.’

The list includes organizations involved in areas such as climate, energy, development, governance, migration and gender policy, according to the White House. The White House published the full list alongside the order.

Rubio said the withdrawals reflect a shift in how the administration views international engagement.

‘We will not continue expending resources, diplomatic capital, and the legitimizing weight of our participation in institutions that are irrelevant to or in conflict with our interests,’ Rubio said. ‘We seek cooperation where it serves our people and will stand firm where it does not.’

The White House and the State Department did not immediately respond to Fox News Digital’s request for comment.

This post appeared first on FOX NEWS

Former Vice President Al Gore on Wednesday condemned President Donald Trump’s move to withdraw the U.S. from United Nations-linked climate initiatives.

Gore claimed in a post on X that ‘the most significant challenge of our lifetimes’ is ‘the climate crisis.’ 

‘The ongoing work of the IPCC, UNFCCC, and other global institutions remains essential to safeguarding humanity’s future,’ he asserted, referring to the Intergovernmental Panel on Climate Change (IPCC), the United Nations Framework Convention on Climate Change (UNFCC).

‘By withdrawing from the IPCC, UNFCCC, and the other vital international partnerships, the Trump Administration is undoing decades of hard-won diplomacy, attempting to undermine climate science, and sowing distrust around the world,’ he wrote.

Trump issued a memorandum ordering U.S. withdrawal from the two initiatives that Gore mentioned as well as scads of other entities.

The president’s memorandum lists the Intergovernmental Panel on Climate Change under a grouping of ‘Non-United Nations Organizations.’ But the website ipcc.ch states, ‘The Intergovernmental Panel on Climate Change (IPCC) is the United Nations body for assessing the science related to climate change.’

In the memorandum, the president declared that he has ‘determined that it is contrary to the interests of the United States to remain a member of, participate in, or otherwise provide support to the organizations listed in section 2 of this memorandum.’

Secretary of State Marco Rubio said in a statement, ‘As this list begins to demonstrate, what started as a pragmatic framework of international organizations for peace and cooperation has morphed into a sprawling architecture of global governance, often dominated by progressive ideology and detached from national interests.’

Gore, who served as vice president alongside Democratic President Bill Clinton, lost the 2000 presidential contest to Republican George W. Bush.

This post appeared first on FOX NEWS

2025 marked a turning point for investment in the cannabis sector, shifting the focus toward operational resilience and consolidation after a sluggish 2024.

Key market drivers included an upswing in merger and acquisition (M&A) activity as stronger multi-state operators (MSOs) acquired distressed assets, alongside pivotal regulatory developments.

The central theme for the year was the expected US federal shift to Schedule III, a policy rollercoaster that culminated in an executive order to expedite rescheduling, focusing investor flows into scaled, cashflow-positive MSOs.

Internationally, incremental legalization in Europe, particularly the momentum in Germany, broadened the global footprint and provided new export channels for North American producers.

Within market trends, profitability pivoted away from bulk flower to high-margin consumables, with infused pre-rolls and edibles driving category growth and supporting a rerating of resilient operators.

US cannabis rescheduling a core shift

After 2024’s punishing drawdowns, cannabis navigated a high-stakes policy rollercoaster in 2025.

The sector bottomed in Q1 as anticipated US Drug Enforcement Administration (DEA) rescheduling hearings were delayed, but ignited in late Q3 and Q4 as the narrative shifted toward a decisive executive-led reclassification.

This momentum culminated in US President Donald Trump’s December 18 executive order, which expedites rescheduling and CBD access. It triggered a parabolic surge followed by a violent ‘sell the news’ correction.

“Cannabis is not just a volatile sector or industry. It is the most volatile place,” said Dan Ahrens, managing director and portfolio manager of the AdvisorShares Pure US Cannabis ETF (ARCA:MSOS). “It just proves the point, once again, that we really, really need this federal reform to be officially completed.”

Indeed, 2025 brought plenty of ups and downs. The year opened with Schedule III buzz, which came after prior Department of Health and Human Services recommendations and initial DEA scheduling proposals from late 2024; however, proceedings ground to a halt after the DEA postponed a key January hearing by over 180 days due to administrative turnover, bias claims and leadership gaps post-election. These disruptiosn kept Section 280E tax penalties in place and banking access frozen, keeping margins for MSOs compressed.

Meanwhile, House spending bills included language prohibiting the Department of Justice (DoJ) from spending any funds on rescheduling efforts, while Senate Farm Bill revisions redefined hemp to exclude intoxicating derivatives like delta-8 THC, capping them at trace levels and effectively imposing a nationwide hemp ban on high-potency alternatives.

The MSOS ETF’s portfolio construction exemplified the broader trend of investor flows concentrating into scaled, cash-flow-positive MSOs amid reform volatility. The fund’s top three holdings — Curaleaf Holdings (CSE:CURA,OTCQX:CURLF), Trulieve Cannabis (CSE:TRUL,OTCQX:TCNNF) and Green Thumb Industries (CSE:GTII,OTCQX:GTBIF) — accounted for over 68 percent of its total holdings as of December 31, underscoring confidence in these operators as resilient proxies for US cannabis maturation while smaller single-state players face dilution.

MSOS managers reinforced the shift in the year’s third quarter by trimming three underperformers from the ETF: 4Front Ventures (CSE:FFNT), Lowell Farms (CSE:LOWL) and Gold Flora.

Despite stalls in momentum, Trump kept hope alive in the cannabis sector throughout the year.

In September, he called cannabis reform an “80-20 issue” with broad public backing, and posted a Truth Social video promoting CBD for seniors and suggesting Medicaid coverage.

Those moves, alongside Representative Greg Steube’s (R-FL) Marijuana 1-to-3 Act, aimed at legislatively shifting cannabis to Schedule III, drove a surge in Q3 without any underlying procedural progress.

As mentioned, the December 18 executive order injected fresh life into the sector, directing the DoJ and DEA to expedite cannabis rescheduling to Schedule III, while launching a CMS Innovation Center pilot for federal health programs to cover hemp-derived CBD as early as April 2026, with up to US$500 annual reimbursement for eligible patients.

CMS Administrator Mehmet Oz previously endorsed Medicare reimbursement for CBD therapies during his confirmation hearings, framing them as “low-risk, high-impact” options for age-related ailments.

European cannabis legalization and international growth

2025 brought incremental legalization or medical frameworks in multiple jurisdictions, including Czechia, Malta, Poland, Switzerland and Luxembourg, broadening the investable global footprint.

This continental momentum has directly boosted North American producers through export ramps and licensing deals, with Canadian licensed producers capturing 43 percent of Germany’s Q2 imports alone.

The country’s CanG framework and adult‑use reform, which came into effect in April 2024, have made it Europe’s most important legal market, with 2025 medical sales expected to see explosive year-on-year growth.

Cannabis company trends in 2025

In 2025, cannabis companies pivoted toward operational resilience and product innovation amid persistent commoditization pressures. After 2024’s wholesale flower price declines, down roughly 32 percent since 2021 by some estimates, stronger MSOs like Tilray Brands (TSX:TLRY,NASDAQ:TLRY) are demonstrating pricing power through branded products and category expansion into edibles, vapes and infused pre-rolls.

Deal flow rebounded from 2024’s US$1.17 billion trough, with US transactions reaching US$2.1 billion.

Against that backdrop, cash-rich MSOs pursued distressed roll-ups in oversupplied states like California and New York, with Vireo Growth’s (CSE:VREO,OTCQX:VREOF) acquisitions in Minnesota and New York exemplifying the trend, achieving critical mass with premium valuations amid hemp restrictions.

Private equity and creative deal structures dominated in the cannabis market, preparing operators for federal reform, while consolidating fragmented retail.

Investor takeaway

2025 marked a transformative year for cannabis, with regulatory breakthroughs and market maturation set against the backdrop of volatility. Trump’s execuctive order has brought new life into the sector in the US with the promise of not only banking and tax relief, but also bipartisan momentum for normalization; however, investors remain cautious.

“Everybody is waiting for it to be real and for it to be completed. Because even though we think the executive order was huge … nothing’s complete yet. Nothing’s official yet,” explained Ahrens.

Looking to 2026, he emphasized that the path forward for cannabis isn’t a straight line, but rather a series of volatile ‘waves’ tied to incremental regulatory milestones. Ahrens anticipates that while the finalization of Schedule III should trigger an initial move, it is merely the first domino; subsequent upside depends on the DoJ providing clear guidance for state-legal adult-use programs and the eventual passage of banking reform.

While he does foresee cannabis stocks uplisting to major exchanges, and Big Pharma companies beginning to make acquisitions in the space, Ahrens remains cautious about timing, noting that even with a signed order, large institutional banks will likely keep the ‘blockade’ in place until the legal ink is truly dry.

Ultimately, while 2025’s executive action has established a concrete foundation for federal reform in the US, the cannabis sector remains poised in a state of high-stakes volatility, with its full maturation dependent on official completion of milestones in 2026 and beyond.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

The growing prevalence of chronic diseases like cancer and diabetes is driving increasing innovation in medical device technology. In 2024 alone, 30 new devices were approved by the US Food and Drug Administration (FDA).

Wearable medical devices and the use of artificial intelligence in medical technology are two key trends in this sector.

Investors who want exposure to this wave of growth may want to consider NASDAQ small-cap medical device stocks. Below is a list of the top NASDAQ medical device companies based on year-on-year gains.

All data was compiled on December 31, 2025, using TradingView’s stock screener, and the medical device makers listed below had market caps between US$50 million and US$500 million at that time.

1. MDxHealth (NASDAQ:MDXH)

Year-on-year gain: 50.86 percent
Market cap: US$173.24 million
Share price: US$3.50

MDxHealth is a commercial-stage precision diagnostics company specializing in molecular tests for urologic cancers, particularly prostate cancer, using genomic, epigenetic and exosomal technologies. Its US headquarters and operations are located in Irvine, California.

The company offers non-invasive and tissue-based diagnostic assays that run on standard PCR platforms.

In September, MDxHealth acquired Exosome Diagnostics from Bio-Techne (NASDAQ:TECH) for US$15 million, adding the ExoDx Prostate urine test to its portfolio. The deal also includes a CLIA-certified clinical laboratory and related assets. The deal is expected to generate over US$20 million in revenue in 2026.

2. KORU Medical Systems (NASDAQ:KRMD)

Year-on-year gain: 50.13 percent
Market cap: US$269.6 million
Share price: US$5.82

KORU Medical Systems develops and manufactures medical devices and supplies in the US and internationally, with a focus on mechanical infusion products. Its Freedom Syringe Infusion System first received FDA clearance in 1994.

Based on this system, its primary products include the Freedom60 and FreedomEdge syringe infusion systems, Precision Flow Rate Tubing and High-Flo Subcutaneous Safety Needle Sets.

KORU Medical Systems submitted a 510(k) premarket notification to the FDA on December 30, 2025, seeking clearance for its FreedomEdge system to deliver Phesgo — a HER2+ breast cancer targeted biologic — subcutaneously, targeting infusion centers to cut chair time and boost efficiency.

The company stated this is part of its strategy to expand the indications of FreedomEdge to the wider oncology infusion center market.

3. Vivani Medical (NASDAQ:VANI)

Year-on-year gain: 1.71 percent
Market cap: US$86.81 million
Share price: US$1.19

Vivani Medical is a clinical-stage biopharmaceutical company developing miniature, long-term subdermal drug implants using its proprietary NanoPortal technology to treat chronic conditions like obesity and type 2 diabetes.

Headquartered in Alameda, California, Vivani focuses on GLP-1 implants that provide steady drug release over six months to improve adherence and tolerability compared to daily pills or weekly injections.

In August, Vivani Medical reported positive Phase 1 results from its LIBERATE-1 trial of the NPM-115 exenatide implant, confirming safety and steady drug release for obesity treatment without major side effects.

The company plans to rapidly advance its NPM-139 semaglutide implant after it achieved preclinical results of sustained 20 percent weight loss. It is planning a Phase 1 clinical study in the first half of 2026.

Securities Disclosure: I, Meagen Seatter, hold no direct investment interest in any company mentioned in this article.

This post appeared first on investingnews.com

(TheNewswire)

Crown Porphyry-Stockwork Drill Targets Confirmed

Vancouver, British Columbia, January 7th, 2026 TheNewswire Prismo Metals Inc. (‘Prismo’ or the ‘Company’) (CSE: PRIZ,OTC:PMOMF) (OTCQB: PMOMF) is pleased to announce it has received final assay results for samples taken at the Silver King Project from the Crown porphyry target area located on the east side of the property (Fig. 1).


Click Image To View Full Size

Figure 1.  Map showing the location of the Crown porphyry and stockwork and Black Diamond replacement exploration targets at the Silver King project.  Claim boundaries are shown in yellow.

Overlimit silver assays have been received for the samples taken in late 2025, showing high grade silver mineralization associated with quartz-sulfide veins hosted by the Crown porphyry (Fig 2, Table 1). These assays provide evidence for a high-priority drill target, especially when taken in conjunction with the high gold assays reported previously for the stockwork intrusion (see the News Release of Dec. 3, 2025).  

‘Prismo optioned Silver King with existing drill targets around the historically significant high-grade silver mine. Based on the geology and its location in a well mineralized region, we believed that additional mineralization was also likely present. Our work in the second half of 2025 indicates that we were correct, and we now have exceptional drill targets at the Crown porphyry and adjacent Black Diamond replacement areas,’ stated Craig Gibson, Chief Exploration Officer of the Company. He added, ‘With the high-grade gold assays reported in December and the copper assays at the Black Diamond replacement, we now have a very significant precious-metal and copper target at Silver King similar to other areas in this well mineralized district that includes the Magma mine and the Resolution copper deposit.’  

‘These additional assay results along with the IP survey information continue to enhance and support our exploration thesis of the Silver King mine and surrounding areas,’ stated Gordon Aldcorn.  ‘This modern-day review has yielded additional drill targets and prospective structures to our program in this already very strategically located project.’

 

Table 1. Assay results for selected samples from the Crown porphyry stockwork

Sample

Location

Easting

Northing

Width m

Au g/t

Ag g/t

Cu %

Pb %

Zn %

544559

Crown porphyry

492681

3687905

0.5 m

0.02

18.91

0.02

0.07

0.04

544561

Crown porphyry

492673

3687904

2 m

0.02

177

0.07

0.37

0.02

544563

Crown porphyry

492613

3687848

0.5m

0.03

176

0.09

0.01

544591*

Crown porphyry

492799

3687851

1.0

5.19

46.44

0.05

0.21

0.06

544592*

Crown porphyry

492793

3687823

1.0

4.06

13.97

0.02

0.10

0.07

*Assays previously released in News Release of December 3, 2025.


Click Image To View Full Size

Figure 2. Precious metal and copper assays from the Crown porphyry
and the Black Diamond replacement body at the Silver King Project.

IP Survey

The Company also completed a pole-dipole IP survey over a part of the Silver King project in December 2025.  This survey was designed to provide some additional 3-dimensional data for areas identified during the initial gradient array survey (see News Release dated December 3, 2025). This new survey confirmed the presence of important chargeability and resistivity anomalies at the Silver King project. The Silver King silver mine appears to be associated with a large low resistivity anomaly located on the contact of the Silver King diorite porphyry (Fig 3). There is also low resistivity anomalies associated with the Crown porphyry and near the replacement mineralization at Black Diamond (Fig 3). The highest chargeability anomalies appear to be associated with the altered country rocks along intrusive contacts, but a chargeability high is also associated with the Crown porphyry stockwork intrusion. The anomaly associated with the Crown porphyry is particularly interesting and can be traced from shallow levels to about 300 meters in depth.  


Click Image To View Full Size

Figure 3. IP resistivity map at a depth of 75 meters, overlain on geology and showing the Silver King glory hole (black line), Black Diamond replacement body in red, and the Crown porphyry-stockwork in magenta.  


Click Image To View Full Size

Figure 4. IP chargeability at a depth of 75 meters, overlain on geology and showing the Silver King glory hole (black line), Black Diamond replacement body in red, and the Crown porphyry-stockwork in magenta.  

Drilling Update

Alain Lambert, CEO of Prismo commented: ‘The results announced today confirm the vast exploration potential at Silver King. While we look forward to drilling these new targets in the future, our plans remain unchanged. Our immediate priority is to undertake our fully funded drill program, as previously announced. This drill campaign will primarily focus on the historic Silver King mine site and will be about 2,000 meters. The objective is to test the upper half of the steeply dipping pipelike Silver King mineralized body as well as potential mineralization adjacent to the dense stockwork that was the focus of historic mining.’

Mr. Lambert added: ‘We are pleased with the steady progress on the permitting front. The collaboration of Forest Service officials demonstrates a clear commitment to supporting mining activities in Arizona.’

Prismo recently announced that the Forest Service, the federal surface land management entity for Silver King, had determined that the Company’s proposed drill plan meets the regulatory requirements for processing, and that such plan is complete, as described in the regulations at 36 CFR 228.4(c).

The Forest Service is currently proceeding with the environmental analysis pursuant to 36 CFR 228(a)(5) in conformity with the National Environmental Policy Act (NEPA). This analysis is proceeding as a Categorical Exclusion, the lowest level of environment reviews applicable to projects that are not expected to have a significant effect on the environment, such as Silver King.

QA/QC

Samples were analyzed by SGS, an internationally recognized analytical lab, with preparation at the Tempe, Arizona facility and analyses at the Burnaby laboratory.  Prismo inserts controls samples consisting of a standard pulps and a coarse blanks in the sample stream, and the lab also inserts control samples.  

Qualified Person

Dr. Craig Gibson, PhD., CPG., a Qualified Person as defined by NI-43-01 regulations and Chief Exploration Officer and a director of the Company, has reviewed and approved the technical disclosures in this news release.  

About Prismo Metals Inc.

Prismo (CSE: PRIZ,OTC:PMOMF) is a mining exploration company focused on advancing its Silver King, Ripsey and Hot Breccia projects in Arizona and its Palos Verdes silver project in Mexico.

Please follow @PrismoMetals on Twitter, Facebook, LinkedIn, Instagram, and YouTube

Prismo Metals Inc.

1100 – 1111 Melville St., Vancouver, British Columbia V6E 3V6 Phone: (416) 361-0737

 

Contact:

Alain Lambert, Chief Executive Officer alain.lambert@prismometals.com

Gordon Aldcorn, President gordon.aldcorn@prismometals.com

  

Neither the Canadian Securities Exchange nor its Market Regulator (as that term is defined in the policies of the Canadian Securities Exchange) accepts responsibility for the adequacy or accuracy of this release.

 

Cautionary Note Regarding Forward-Looking Information

This release includes certain statements and information that may constitute forward-looking information within the meaning of applicable Canadian securities laws. Forward-looking statements relate to future events or future performance and reflect the expectations or beliefs of management of the Company regarding future events. Generally, forward-looking statements and information can be identified by the use of forward-looking terminology such as intends’ or anticipates’, or variations of such words and phrases or statements that certain actions, events or results may’, could’, should’, would’ or occur’. This information and these statements, referred to herein as ‘forward-looking statements’, are not historical facts, are made as of the date of this news release and include without limitation, statements regarding discussions of future plans, estimates and forecasts and statements as to management’s expectations and intentions with respect to, among other things: the timing, costs and results of drilling at Silver King; and the intended use of any proceeds raised under recent financings.

These forward-looking statements involve numerous risks and uncertainties, and actual results might differ materially from results suggested in any forward-looking statements. These risks and uncertainties include, among other things: the potential inability of the Company to utilize the anticipated proceeds of the Private Placement as anticipated; and those risks set out in the Company’s public disclosure record on SEDAR+ (www.sedarplus.com) under the Company’s issuer profile.

In making the forward-looking statements in this news release, the Company has applied several material assumptions, including without limitation, that the Company will use the proceeds of the Second Tranche as currently anticipated and on the timeline currently expected.

Although management of the Company has attempted to identify important factors that could cause actual results to differ materially from those contained in forward-looking statements or forward- looking information, there may be other factors that cause results not to be as anticipated, estimated or intended. There can be no assurance that such statements will prove to be accurate, as actual results and future events could differ materially from those anticipated in such statements. Accordingly, readers should not place undue reliance on forward-looking statements and forward- looking information. Readers are cautioned that reliance on such information may not be appropriate for other purposes. The Company does not undertake to update any forward-looking statement, forward-looking information or financial outlook that are incorporated by reference herein, except in accordance with applicable securities laws. We seek safe harbor.

Copyright (c) 2026 TheNewswire – All rights reserved.

News Provided by TheNewsWire via QuoteMedia

This post appeared first on investingnews.com